Search Clinical Trials in the European Union
Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1661-1680 of 2,120 trials
Psoriatic Arthritis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatologyRheumatology
Psoriatic Arthritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatologyRheumatology
Stage IV Colorectal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology
Relapsed or Refractory B-Cell Malignancies>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology
Cryoglobulinemia Vasculitis6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementInfectious DiseasesRheumatology
Wrist Osteoarthritis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOrthopedics and TraumatologyRheumatology
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology
Hereditary Angioedema3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine
Iron Deficiency Anemia≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHematologyPediatrics
Yeast Intra-Abdominal Infection (Peritonitis)>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesInfectious DiseasesInternal Medicine
Liver Cirrhosis>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyInternal Medicine
Sjögren's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInfectious DiseasesRheumatology
Connective Tissue Disease with Risk of Lung Disease1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPulmonologyRheumatology
Slipped Capital Femoral Epiphysis (SCFE)Legg-Calvé-Perthes Disease (LCPD)Neuromuscular ConditionsMonitoring phase (IV)Standard MedicinesOrthopedics and TraumatologyPediatrics
Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesOncology